1型糖尿病患者血浆脂蛋白(a)水平与心血管疾病患病率及代谢控制状态的关联
这项观察性横断面研究纳入1860例接受常规治疗的1型糖尿病患者,按脂蛋白(a)水平分为四组,比较血管并发症患病率。高脂蛋白(a)组大血管病变、白蛋白尿和钙化性主动脉瓣疾病的相对危险比升高;代谢控制良好者脂蛋白(a)水平显著低于控制较差者。
要点
- 高脂蛋白(a)组大血管病变相对危险比为1.51(95%CI 1.01-2.28,P=0.048)。
- 高脂蛋白(a)组白蛋白尿相对危险比为1.68(95%CI 1.12-2.50,P=0.01)。
- 高脂蛋白(a)组钙化性主动脉瓣疾病相对危险比为2.03(95%CI 1.03-4.03,P=0.042)。
核心结论
- 脂蛋白(a)是1型糖尿病患者大血管病变、白蛋白尿和钙化性主动脉瓣疾病的显著危险因素。
- 1型糖尿病代谢控制较差与脂蛋白(a)水平升高相关。
研究设计与样本
- 观察性横断面研究,纳入接受常规治疗的1型糖尿病患者1860例。
- 按脂蛋白(a)水平(nmol/L)分为四组:极低<10、低10-30、中间30-120、高>120。
- 比较各组血管并发症患病率,并分析HbA1c与脂蛋白(a)的关联。
主要发现
- 患者中位年龄48岁,糖尿病病程25年,HbA1c 7.8%(61 mmol/mol)。
- 脂蛋白(a)中位数19 nmol/L(四分位距10-71)。
- 男女间无显著差异,脂蛋白(a)水平随年龄增加而升高。
- 高脂蛋白(a)组并发症患病率高于极低脂蛋白(a)组。
- 年龄和吸烟状态调整后,高脂蛋白(a)组患任何大血管疾病的相对危险比为1.51(95%CI 1.01-2.28,P=0.048);冠心病为1.70(95%CI 0.97-3.00,P=0.063);白蛋白尿为1.68(95%CI 1.12-2.50,P=0.01);钙化性主动脉瓣疾病为2.03(95%CI 1.03-4.03,P=0.042)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the association of the cardiovascular risk factor lipoprotein (Lp)(a) and vascular complications in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: Patients with type 1 diabetes receiving regular care were recruited in this observational cross-sectional study and divided into four groups according to their Lp(a) levels in nmol/L (very low <10, low 10-30, intermediate 30-120, high >120). Prevalence of vascular complications was compared between the groups. In addition, the association between metabolic control, measured as HbA1c, and Lp(a) was studied. RESULTS: The patients (n = 1,860) had a median age of 48 years, diabetes duration of 25 years, and HbA1c of 7.8% (61 mmol/mol). The median Lp(a) was 19 (interquartile range 10-71) nmol/L. No significant differences between men and women were observed, but Lp(a) levels increased with increasing age. Patients in the high Lp(a) group had higher prevalence of complications than patients in the very low Lp(a) group. The age- and smoking-status-adjusted relative risk ratio of having any macrovascular disease was 1.51 (95% CI 1.01-2.28, P = 0.048); coronary heart disease, 1.70 (95% CI 0.97-3.00, P = 0.063); albuminuria, 1.68 (95% CI 1.12-2.50, P = 0.01); and calcified aortic valve disease, 2.03 (95% CI 1.03-4.03; P = 0.042). Patients with good metabolic control, HbA1c <6.9% (<52 mmol/mol), had significantly lower Lp(a) levels than patients with poorer metabolic control, HbA1c >6.9% (>52 mmol/mol). CONCLUSIONS: Lp(a) is a significant risk factor for macrovascular disease, albuminuria, and calcified aortic valve disease in patients with type 1 diabetes. Poor metabolic control in patients with type 1 diabetes is associated with increased Lp(a) levels.
引用
- Littmann K, Wodaje T, Alvarsson M, et al. The Association of Lipoprotein(a) Plasma Levels With Prevalence of Cardiovascular Disease and Metabolic Control Status in Patients With Type 1 Diabetes. Diabetes Care. 2019. PMID: 31862789. doi:10.2337/dc19-1398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。